Clinical Trials

The purpose of this study is to assess optimal dosing frequency, effectiveness and safety of adipose-derived autologous mesenchymal stem cells delivered into the spinal fluid of patients with multipe system atrophy (MSA).

Multiple system atrophy (MSA) is a rare, rapidly progressive, and invariably fatal neurological condition characterized by autonomic failure, parkinsonism, and/or ataxia. There is no available treatment to slow or halt disease progression. 

The purpose of this study is to compare the effectiveness of BHV-3241 versus placebo in subjects with Multiple System Atrophy.

The purpose of this study is to evaluate the effectiveness of Lu AF82422 on disease progression in patients with Multiple System Atrophy (MSA).

The purpose of this study is to validate use of a modified Unified Multiple System Atrophy Rating Scale (UMSARS) that incorporates structured questions and additional instructions, developed by Biohaven Pharmaceuticals based on feedback from the FDA, as the primary outcome variable for assessing clinically meaningful change in Biohaven’s Phase 3 Multiple System Atrophy (MSA) Study BHV3241-301.

The primary purpose of this study is to understand the influence of sex and gender on pathophysiologic mechanisms of neurodegeneration in Multiple System Atrophy (MSA) in order to determine sex-specific hormonal factors associated with onset of symptoms in MSA.

The purpose of this study is to determine the effectiveness of Rifampicin  in slowing or reversing the progression of multiple system atrophy.

The purpose of this study is to compare the effectiveness of BHV-3241 versus placebo in subjects with Multiple System Atrophy.

The goals of the study are to prospectively evaluate clinical and laboratory biomarkers of multiple system atrophy and Parkinson’s disease at early clinical disease, at a premotor stage (PAF), and even at a prodromal stage (RBD).

1. To evaluate whether SSRI use is associated with increased survival time and slower disease progression among patients with MSA.

2. To evaluate whether SSRI use is associated with the presence of clinical respiratory insufficiency such as stridor.

The purpose of this study is to understand why patients with multiple system atrophy, Parkinson’s disease, Parkinson’s disease with autonomic failure, and dementia with Lewy bodies have a fall in blood pressure on standing up. It is believed that different patients develop these symptoms for different reasons. The reasons could be:

• damage to nerve supply to the legs

• the autonomic nerves are not working properly

• the brain is not controlling blood pressure or heart rate properly

This study will look at these different reasons.

The purpose of this research study is to better understand why patients with a disease that causes problems with the autonomic nervous system often have high blood pressure when they lie down. We hope that if we learn more about the cause for this problem, we will be able to treat the problem better in the future.

The purpose of this study is to develop a diagnostic test using tissue biomarkers to provide an accurate diagnosis of alpha-synucleinopathies in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguishing between neurodegenerative diseases.

Most individuals with rapid eye movement (REM) sleep behavior disorder (RBD) develop additional
neurological symptoms and are subsequently diagnosed with overt synucleinopathies, including dementia with
Lewy bodies (DLB), Parkinson disease (PD), and multiple system atrophy (MSA), indicating that RBD
represents a prodromal stage of synucleinopathy. RBD therefore offers a window of opportunity to intervene
with neuroprotective treatments at the earliest stages of disease when treatment is most likely to be effective.
Recognizing the importance of early intervention, key federal agencies focused on neurodegenerative disease
have proposed high priority recommendations for prodromal aspects of synucleinopathies, including
specifically RBD, to prepare for ...

The purpose of this study is to study the structure and biochemistry of the brain and/or bodily fluid and tissue after death.  Comparison of specimens from normal and diseased individuals provide essential clues that lead to a greater understanding of the diseased state which, in turn, will lead to new ideas for therapy.